Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline
Open Access
- 26 September 2021
- journal article
- review article
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 19 (1) , 1-7
Abstract
Objective: The purpose of this guideline is to make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2. Methods: Draft recommendations were formulated based on evidence obtained through a systematic review of RCTs, comparative retrospective studies and guideline endorsement. The draft recommendations underwent an internal review by clinical and methodology experts, and an external review by clinical practitioners. Results: The literature search yielded 1 guideline, 5 systematic reviews, and 15 studies that met the eligibility criteria. Conclusions: In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 screening for ovarian cancer is not recommended. Risk-reducing surgery is recommended to reduce the risk of ovarian cancer. In the absence of contraindications, premenopausal women undergoing RRSO should be offered hormone therapy until menopause. Systemic hormone replacement therapy, is not recommended for women who have had a personal history of breast cancer. RRSO should be considered for breast cancer risk reduction in women younger than 50 years. After a breast cancer diagnosis, RRSO for breast cancer mortality reduction can be considered within two years to women who harbour a pathogenic or likely pathogenic variant in BRCA1 if younger than the recommended age range for ovarian cancer risk reduction. RRSO before the age of 40 and specifically for breast cancer treatment in BRCA2 should be considered only if recommended by their breast cancer oncologist. Following RRSO, it is not recommended to do surveillance for peritoneal cancer.Keywords
This publication has 34 references indexed in Scilit:
- Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening testsHereditary Cancer in Clinical Practice, 2011
- AGREE II: advancing guideline development, reporting and evaluation in health careCanadian Medical Association Journal, 2010
- Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?International Journal of Cancer, 2008
- A randomized study of screening for ovarian cancer: a multicenter study in JapanInternational Journal of Gynecological Cancer, 2008
- Ovarian cancer screening with annual transvaginal sonographyCancer, 2007
- Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 MutationJAMA, 2006
- Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort studyInternational Journal of Gynecological Cancer, 2006
- CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancerGynecologic Oncology, 2006
- Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics SystemJournal of Clinical Oncology, 2005
- Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA MutationsJournal of Clinical Oncology, 2003